SNGX - Soligenix, Inc. Discussion

Discussion (94)

Target high SNGX Jun 24, 2025 1 year ago #1

$SNGX what happened? Any one has any clue? Any buying opportunity? Or time to dump the holding.

CAD CAM SNGX Oct 4, 2024 2 years ago #2

Overview:

textCopy

•	Company: Soligenix, Inc. (Ticker: SNGX on NASDAQ)
•	Current Stock Price: $4.87 (as of October 3, 2024)
•	Valuation: $35.00 per share
•	Industry: Med-Biomed/Gene
•	Risk Level: High

Company Focus:

Soligenix is developing a vaccine for Marburg virus called MarVax™. This vaccine is based on Soligenix’s proprietary ThermoVax® technology, which allows for stability at elevated temperatures. It has shown 100% protection in non-human primates and could be a breakthrough if clinical trials are successful.

Recent Events:

textCopy

•	An outbreak of Marburg virus in Rwanda has resulted in 26 confirmed cases and 8 deaths.
•	Two travelers who had been in Rwanda were hospitalized in Hamburg, Germany with symptoms consistent with the Marburg virus.
•	The WHO assessed the risk for Rwanda as “very high” and “high” at the regional level.
•	Soligenix’s Marburg vaccine program has gained attention as a result of this outbreak.

Financial Overview:

textCopy

•	52-Week High: $15.68
•	52-Week Low: $2.00
•	Market Capitalization: $11 million
•	Average Daily Volume: 194,874 shares
•	Institutional Ownership: 4%
•	Insider Ownership: 3%

Projected Financials (2023-2026):

textCopy

•	The company expects minimal revenues until 2026, with projected earnings losses for the foreseeable future.
•	Revenue is mainly derived from grants and contracts, as the company is still in the development stage for most of its products.

Outlook and Valuation:

textCopy

•	The valuation of $35.00 per share is based on a probability-adjusted discounted cash flow (DCF) model considering potential future revenues from its product pipeline, including HyBryte™, SGX302, and SGX945.
•	This valuation is highly contingent upon clinical success and future developments.

Summary:

The report emphasizes that the ongoing Marburg outbreak underscores the need for effective vaccines, and Soligenix’s developments position it as a potential key player in this field. The company’s technology offers advantages such as extended stability and high efficacy in non-human primate models.

The research report concludes with a cautiously optimistic outlook, noting that updates on clinical trials and regulatory meetings are expected in the next 12 months.